Cardiac hypertrophy is associated with altered thioredoxin and ASK-1 signaling in a mouse model of menopause

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 4, 2008, Pages

  Ebrahimian, Talin ^a   Sairam, M Ram ^b   Schiffrin, Ernesto L ^a   Touyz, Rhian M ^c  

^a MCGILL UNIVERSITY   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Blood pressure; Oxidative stress

Indexed keywords

ANTIOXIDANT; APOPTOSIS SIGNAL REGULATING KINASE 1; FOLLITROPIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOCRINE DISEASE; ENZYME ACTIVITY; EXPERIMENTAL MOUSE; FEMALE; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; KNOCKOUT MOUSE; MENOPAUSE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TARGET ORGAN; WILD TYPE;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; BLOOD PRESSURE; BLOTTING, WESTERN; CARDIOMEGALY; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FOLLICLE STIMULATING HORMONE; HYPERTENSION; MAP KINASE KINASE KINASE 5; MENOPAUSE; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; OXIDATIVE STRESS; PHOSPHORYLATION; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; SUPEROXIDE DISMUTASE; THIOREDOXINS; TIME FACTORS;

EID: 57049142195     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00163.2008     Document Type: Article

References (47)

1. Ago T, Sadoshima J. Thioredoxin1 as a negative regulator of cardiac hypertrophy. Antioxid Redox Signal 9: 679-687, 2007.
2. Ashraf MS, Vongpatanasin W. Estrogen and hypertension. Curr Hypertens Rep 8: 368-376, 2006.
3. Burke-Gaffney A, Callister ME, Nakamura H. Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26: 398-404, 2005.
4. Danilovich N, Babu PS, Xing W, Gerdes M, Krishnamurthy H, Sairam MR. Estrogen deficiency, obesity, and skeletal abnormalities in follicle-stimulating hormone receptor knockout (FORKO) female mice. Endocrinology 141: 4295-4308, 2000.
5. Deroo BJ, Hewitt SC, Peddada SD, Korach KS. Estradiol regulates the thioredoxin antioxidant system in the mouse uterus. Endocrinology 145: 5485-5492, 2004.
6. Ebrahimian T, He Y, Schiffrin EL, Touyz RM. Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J Hypertens 25: 1263-1271, 2007.
7. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J 10: 615-624, 1996.
8. Gasdaska JR, Berggren M, Powis G. Cell growth stimulation by the redox protein thioredoxin occurs by a novel helper mechanism. Cell Growth Differ 6: 1643-1650, 1995.
9. Gurusamy N, Malik G, Gorbunov NV, Das DK. Redox activation of Ref-1 potentiates cell survival following myocardial ischemia reperfusion injury. Free Radic Biol Med 43: 397-407, 2007.
10. 1 receptor and salt sensitivity. Hypertension 42: 1157-1163, 2003.
11. Head GA, Obeyesekere VR, Jones ME, Simpson ER, Krozowski ZS. Aromatase-deficient (ArKO) mice have reduced blood pressure and baroreflex sensitivity. Endocrinology 145: 4286-4291, 2004.
12. Hernandez I, Delgado JL, Diaz J, Quesada T, Teruel MJ, Llanos MC, Carbonell LF. 17β-Estradiol prevents oxidative stress and decreases blood pressure in ovariectomized rats. Am J Physiol Regul Integr Comp Physiol 279: R1599-R1605, 2000.
13. Holmgren A. Bovine thioredoxin system. Purification of thioredoxin reductase from calf liver and thymus and studies of its function in disulfide reduction. J Biol Chem 252: 4600-4606, 1977.
14. Hoshino Y, Shioji K, Nakamura H, Masutani H, Yodoi J. From oxygen sensing to heart failure: role of thioredoxin. Antioxid Redox Signal 9: 689-699, 2007.
15. Iliescu R, Cucchiarelli VE, Yanes LL, Iles JW, Reckelhoff JF. Impact of androgen-induced oxidative stress on hypertension in male SHR. Am J Physiol Regul Integr Comp Physiol 292: R731-R735, 2007.
16. Javeshghani D, Sairam MR, Neves MF, Schiffrin EL, Touyz RM. Angiotensin II induces vascular dysfunction without exacerbating blood pressure elevation in a mouse model of menopause-associated hypertension. J Hypertens 24: 1365-1373, 2006.
17. Javeshghani D, Touyz RM, Sairam MR, Virdis A, Neves MF, Schiffrin EL. Attenuated responses to angiotensin II in follitropin receptor knockout mice, a model of menopause-associated hypertension. Hypertension 42: 761-767, 2003.
18. 3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164: 6287-6295, 2000.
19. Kasuno K, Nakamura H, Ono T, Muso E, Yodoi J. Protective roles of thioredoxin, a redox-regulating protein, in renal ischemia/reperfusion injury. Kidney Int 64: 1273-1282, 2003.
20. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension 25: 1111-1115, 1995.
21. Lam KK, Lee YM, Hsiao G, Chen SY, Yen MH. Estrogen therapy replenishes vascular tetrahydrobiopterin and reduces oxidative stress in ovariectomized rats. Menopause 13: 294-302, 2006.
22. Lee Y, Vassilakos A, Feng N, Avolio T, Jin H, Viau S, Wang M, Courssaris B, Xiong K, Wright J, Young A. Anti-proliferative and anti-tumor effects of antisense oligonucleotide GTI-2601 targeted against human thioredoxin. Anticancer Drugs 17: 143-154, 2006.
23. Liu H, Zhang H, Iles KE, Rinna A, Merrill G, Yodoi J, Torres M, Forman HJ. The ADP-stimulated NADPH oxidase activates the ASK-1/MKK4/JNK pathway in alveolar macrophages. Free Radic Res 40: 865-874, 2006.
24. Liu Y, Min W. Thioredoxin promotes ASK1 ubiquitination and degradation to inhibit ASK1-mediated apoptosis in a redox activity-independent manner. Circ Res 90: 1259-1266, 2002.
25. Neugarten J. Estrogen and oxidative stress. Gend Med 4: 31-32, 2007.
26. Okuda M, Inoue N, Azumi H, Seno T, Sumi Y, Hirata K, Kawashima S, Hayashi Y, Itoh H, Yodoi J, Yokoyama M. Expression of glutaredoxin in human coronary arteries: its potential role in antioxidant protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21: 1483-1487, 2001.
27. Patwari P, Lee RT. Thioredoxins, mitochondria, hypertension. Am J Pathol 170: 805-808, 2007.
28. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension 43: 918-923, 2004.
29. Rosano GM, Vitale C, Marazzi G, Volterrani M. Menopause and cardiovascular disease: the evidence. Climacteric 10, Suppl 1: 19-24, 2007.
30. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
31. Sartori-Valinotti JC, Iliescu R, Fortepiani LA, Yanes LL, Reckelhoff JF. Sex differences in oxidative stress and the impact on blood pressure control and cardiovascular disease. Clin Exp Pharmacol Physiol 34: 938-945, 2007.
32. Satoh M, Matter CM, Ogita H, Takeshita K, Wang CY, Dorn GW 2nd, Liao JK. Inhibition of apoptosis-regulated signaling kinase-1 and prevention of congestive heart failure by estrogen. Circulation 115: 3197-3204, 2007.
33. Spyrou G, Enmark E, Miranda-Vizuete A, Gustafsson J. Cloning and expression of a novel mammalian thioredoxin. J Biol Chem 272: 2936-2941, 1997.
34. Tanito M, Nakamura H, Kwon YW, Teratani A, Masutani H, Shioji K, Kishimoto C, Ohira A, Horie R, Yodoi J. Enhanced oxidative stress and impaired thioredoxin expression in spontaneously hypertensive rats. Antioxid Redox Signal 6: 89-97, 2004.
35. Tatchum-Talom R, Eyster KM, Martin DS. Sexual dimorphism in angiotensin II-induced hypertension and vascular alterations. Can J Physiol Pharmacol 83: 413-422, 2005.
36. Touyz RM, Yao G, Quinn MT, Pagano PJ, Schiffrin EL. p47phox associates with the cytoskeleton through cortactin in human vascular smooth muscle cells: role in NAD(P)H oxidase regulation by angiotensin II. Arterioscler Thromb Vasc Biol 25: 512-518, 2005.
37. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, Schiffrin EL. Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arterioscler Thromb Vasc Biol 23: 1352-1357, 2003.
38. 1 receptor translation. Endocrinology 144: 3251-3261, 2003.
39. Xue B, Pamidimukkala J, Hay M. Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am J Physiol Heart Circ Physiol 288: H2177-H2184, 2005.
40. Yamagata K, Tagami M, Ikeda K, Yamori Y, Nara Y. Altered gene expressions during hypoxia and reoxygenation in cortical neurons isolated from stroke-prone spontaneously hypertensive rats. Neurosci Lett 284: 131-134, 2000.
41. Yamaleyeva LM, Pendergrass KD, Pirro NT, Gallagher PE, Groban L, Chappell MC. Ovariectomy is protective against renal injury in the high-salt-fed older mRen2.Lewis rat. Am J Physiol Heart Circ Physiol 293: H2064-H2071, 2007.
42. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X, Wagner T, Vatner SF, Sadoshima J. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 112: 1395-1406, 2003.
43. Yamawaki H, Haendeler J, Berk BC. Thioredoxin: a key regulator of cardiovascular homeostasis. Circ Res 93: 1029-1033, 2003.
44. Yanes LL, Romero DG, Iles JW, Iliescu R, Gomez-Sanchez C, Reckelhoff JF. Sexual dimorphism in the renin-angiotensin system in aging spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 291: R383-R390, 2006.
45. Yoshioka J, Imahashi K, Gabel SA, Chutkow WA, Burds AA, Gannon J, Schulze PC, MacGillivray C, London RE, Murphy E, Lee RT. Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res 101: 1328-1338, 2007.
46. Yoshioka J, Schulze PC, Cupesi M, Sylvan JD, MacGillivray C, Gannon J, Huang H, Lee RT. Thioredoxin-interacting protein controls cardiac hypertrophy through regulation of thioredoxin activity. Circulation 109: 2581-2586, 2004.
47. Zhou MS, Jaimes EA, Raij L. Vascular but not cardiac remodeling is associated with superoxide production in angiotensin II hypertension. J Hypertens 23: 1737-1743, 2005.